Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
REDMOND, Wash., March 18, 2026 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”), the global leader in Pattern Discovery, today announced expanded global intellectual property...
-
Deep Origin announced the promotion of Natalie Ma to Chief Business Officer. The company also welcomes Mostafa Ahmed as Senior Principal Scientist.
-
Organoid COMMONS appoints its Governing Board and Alliance Director. Member applications are open through April 30, 2026.
-
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia.
-
Newly discovered drug leverages the power of Pattern Discovery Engine™ (PDE) and is an extension of 2025 study wherein Pattern developed novel risk assessment tool, discovered new drug target for...
-
The acquisition encompasses Quantum’s proprietary intellectual property portfolio, including an innovative patent for AI-Quantum Error Correction Tel Aviv, Israel, March 04, 2026 (GLOBE NEWSWIRE)...
-
Dublin, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The "Medical & Clinical Research - Industry Report" report has been added to ResearchAndMarkets.com's offering. A quick glance of this Medical...
-
MindRank, artificial intelligence (AI)-empowered drug discovery company, announced FPI in Phase III Trial of an Oral GLP-1 Receptor Agonist MDR-001.
-
Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The "Variations to Marketing Authorisations Training Course (June 2nd - June 3rd, 2026)" training has been added to ResearchAndMarkets.com's offering. ...
-
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead...